Newron Pharmaceuticals Discusses FDA Clinical Hold on ENIGMA-TRS Program

Key Facts

Newron Pharmaceuticals discussed an FDA clinical hold and safety concerns regarding its ENIGMA-TRS program for treatment-resistant schizophrenia. Seeking Alpha reported that the company held a discussion to address the regulatory feedback and the next steps for the clinical study.

The program focuses on developing evenamide for patients with poorly responding schizophrenia, a field where therapeutic options remain extremely limited. The clinical hold is viewed as a significant regulatory setback that typically delays commercialization and increases safety risks.